# EDGAR Filing Document

**Accession Number:** 0001799207
**File Stem:** 0000950103-25-015107
**Filing Date:** 2025-11
**Character Count:** 161526
**Document Hash:** fa816277edbfcaa88de816364c0efeb0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-25-015107.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0000950103-25-015107

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251120

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AUNA S.A.
- **CENTRAL INDEX KEY:** 0001799207
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41982
- **FILM NUMBER:** 251503825

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 6, RUE JEAN MONNET
- **CITY:** GRAND DUCHY OF LUXEMBOURG
- **PROVINCE COUNTRY:** N4
- **ZIP:** L-2180
- **BUSINESS PHONE:** 51 (205-3500)

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 6, RUE JEAN MONNET
- **CITY:** GRAND DUCHY OF LUXEMBOURG
- **PROVINCE COUNTRY:** N4
- **ZIP:** L-2180

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AUNA S.A.A.
- **DATE OF NAME CHANGE:** 20200930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AUNA S.A.
- **DATE OF NAME CHANGE:** 20200108

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 <br> OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November 2025

**Commission File Number: 001**-**41982**

**Auna S.A.**

**(Exact name of registrant as specified in its charter)**

**6, rue Jean Monnet**

**L-2180 Luxembourg**

**Grand Duchy of Luxembourg**

**‎+51 1-205-3500‎**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F X Form 40-F  

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **EXHIBIT** |  |
| [99.1](dp237728_ex9901.htm) | [Press release dated November 20, 2025 — Auna announces 3Q25 Financial Results](dp237728_ex9901.htm)  |
| [99.2](dp237728_ex9902.htm) | [Unaudited Condensed Consolidated Interim Financial Statements as of and for the three-month and nine-month period ended September 30, 2025](dp237728_ex9902.htm)  |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **Auna S.A.** | **Auna S.A.** | **Auna S.A.** |
| By: | /s/ Gisele Remy | /s/ Gisele Remy |
|  | Name: | Gisele Remy |
|  | Title: | Chief Financial Officer |

---

Date: November 20, 2025

## Exhibit 99.1

**Exhibit 99.1**

**Auna Announces 3Q25 Financial Results**

**Auna Delivers Solid Financial and Operating Performance in Peru and Colombia, While Advancing Key Initiatives in Mexico**

**Luxembourg, Nov 20, 2025 – Auna (NYSE: AUNA) ("Auna" or the "Company")**, a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, announced today financial results for the third quarter ended September 30, 2025 ("third quarter 2025" or "3Q25"). Financial results are expressed in Peruvian Soles ("S/" or PEN") and are presented in accordance with International Financial Reporting Standards ("IFRS"), unless otherwise noted.

3Q25 Consolidated Highlights

● Consolidated Revenue increased 1% FXN, while decreasing 1% YoY on reported basis, to S/1,117 million

● Adjusted EBITDA decreased 5% FXN, or 7% YoY on reported basis, to S/232 million

● Adjusted EBITDA Margin of 20.8%, down 1.3 p.p. YoY from 22.1%

● Adjusted Net Income was S/58 million, down from S/75 million in 3Q24

● Leverage Ratio remains unchanged at 3.6x

● Mexico's surgeries and oncology services increased for the second consecutive quarter

● Oncology MLR decreased to 49.3%

Message from Auna's Executive Chairman and President

Despite weaker financial yet promising operational results, the third quarter of 2025 demonstrates the enduring resilience of Auna's integrated regional healthcare platform and the robust performance of our operations. The operations in Peru and Colombia achieved substantial growth and profitability in local currency, despite challenging macroeconomic conditions, while in our Mexico business, which is slowly recovering from previously communicated challenges, hospital operations remained stable, although the segment delivered less favorable financial results.

In Peru, both Oncosalud and Healthcare Services delivered consistently strong performance levels, supported by growth in memberships, annual pricing adjustments, and the sustained improvement of the Oncology MLR to 49.3%. The disciplined containment of costs and the operational efficiency of our medical talent continued to underpin this performance.

Our results were strong in Colombia, with double-digit growth in Adjusted EBITDA and continued expansion of risk-sharing Prospective Global Payment ("PGP") models. The team's focus on reducing exposure to intervened payors and optimizing resource utilization supported profitability and improved cash generation.

In Mexico, despite a second consecutive quarterly increase in the number of surgeries and growth in oncology and cardiology services, revenues and profitability declined year over year due to still lackluster demand for medical procedures, a sluggish recovery of volumes affected by legacy physician and supplier relationships, and migration issues related to the implementation of new Hospital Information and ERP systems at Doctors Hospital, which we expect to resolve in the coming months.

At the consolidated level, our leverage remained stable at 3.6x Net Debt-to-Adjusted EBITDA, reflecting a disciplined approach to capital allocation, a robust cash position, and continued progress toward our medium-term deleveraging objective of below 3x. Additionally, following quarter-end, Auna completed a USD765 million debt refinancing that extends debt maturities, reduces interest costs, and further fortifies Auna's capital structure. Complementing these efforts, the announcement of our partnership with Sojitz and the recent Trecca milestone underscore the confidence in our strategy in Mexico and the significant opportunities that remain in Peru, while allowing us to pursue this growth maintaining our deleveraging path and our target of bringing leverage below 3x.

We remain focused on recovering our fast-pace of growth, rolling-out the AunaWay in Mexico, further strengthening operational performance, and expanding patient access to high-quality healthcare across Spanish-speaking Latin America.

Overview of 3Q25 Consolidated Results

**Revenues** increased 1% FXN and decreased 1% YoY on a reported basis to S/1,117 million, with revenues in local currency ("LC") increasing 9% in Peru and 4% in Colombia, offset by a 12% decrease in Mexico. In Mexico, healthcare network revenue decreased, partly due to softer demand for emergency and surgical procedures and to the slow recovery of volumes following the physician and supplier relationships challenges experienced in the first quarter of this year. Mexico's results also included the impact of the ongoing implementation of a new Hospital Information System and ERP at Doctors Hospital. In Peru, Oncosalud Peru contributed higher revenues with an increase in plan memberships and average ticket, while the healthcare network experienced higher demand for emergency visits and ambulatory care. In Colombia, revenue growth was driven by an increase in PGPs, increasing diversification away from intervened payors, and higher surgery tickets.

**Adjusted EBITDA** decreased 5% FXN, 7% YoY on a reported basis to S/232 million, with an Adjusted EBITDA Margin of 20.8%. Adjusted EBITDA increased 15% in Peru and 18% in Colombia in LC, offset by a 29% decrease in Mexico. In Mexico, Adjusted EBITDA

decreased primarily on lower revenue and lower gross profit, while Peru's increased on higher gross profit, supported by growth in its Healthcare Services segment and higher membership sales in Oncosalud. Colombia achieved higher gross profit and lower impairment losses compared to the prior year's quarter. As reported results were impacted by depreciations of the MXN by 5% and of the COP by 4%, both versus PEN.

**Net finance costs** were S/72 million in 3Q25 compared to S/103 million in 3Q24. Excluding FX effects, net finance costs would have been S/111 million in 3Q25 and S/132 million in 3Q24, representing a decrease of S/20 million or 16%. The FX impact in 3Q25 included a positive non-cash amount of S/40 million, compared to a positive S/28 million in 3Q24, primarily reflecting the appreciation of the Peruvian Sol against the US Dollar below the range of Auna's call-spread hedge.

**Net Income** was S/53 million in 3Q25 compared to S/101 million in 3Q24. On a per-share basis, Auna reported Net Income of S/0.65, based on a weighted average number of basic and diluted shares of 74,188,937.

**Adjusted Net Income**, was S/58 million in 3Q25 versus S/75 million in 3Q24. On a per-share basis, Auna reported Adjusted Net Income of S/0.71, based on a weighted average number of basic and diluted shares of 74,188,937.

Business performance

**HEALTHCARE SERVICES MEXICO** 

*(Explanations of variances are in local currency unless expressed otherwise)*

Auna's Healthcare Services and Auna Seguros' operations in Mexico accounted for 24% of consolidated revenues and 33% of consolidated Adjusted EBITDA.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| |  | | | | **Δ 3Q'25 vs 3Q'24** | **Δ 3Q'25 vs 3Q'24** | **Δ 3Q'25 vs 2Q'25** | **Δ 3Q'25 vs 2Q'25** | **Δ YTD 25 vs YTD 24** | **Δ YTD 25 vs YTD 24** |
| <br>**Healthcare Services Mexico<br> Key Operating Metrics** | | <br>**3Q'25 (USD)** | <br>**3Q'25** | <br>**YTD 25** | **As Reported** | **L.C.** | **As Reported** | **L.C.** | **As Reported** | **L.C.** |
| Beds | # |  | 708 | 708 | 0% |  | 0% |  | 0% |  |
| Surgeries | *# (000)* |  | 5 | 15 | -8% |  | 6% |  | -7% |  |
| Emergency treatments | *# (000)* |  | 7 | 23 | -16% |  | -11% |  | -14% |  |
| Operating capacity utilization | % |  | 58.7% | 58.8% | -6.5 p.p. |  | 0.9 p.p. |  | -4.5 p.p. |  |
| Total capacity utilization | % |  | 39.1% | 39.1% | -4.4 p.p. |  | 0.6 p.p. |  | -3.0 p.p. |  |
| **Key Financial Metrics** |  |  |  |  |  |  |  |  |  |  |
| Segment Revenue |  | 76 | 264 | 781 | -16% | -12% | -3% | -5% | -16% | -4% |
| Segment Adjusted EBITDA |  | 22 | 77 | 245 | -32% | -29% | -13% | -14% | -23% | -12% |
| *Segment Adjusted EBITDA margin* | *%* |  | *29.0%* | *31.4%* | *-6.9 p.p.* |  | *-3.0 p.p.* |  | *-2.9 p.p.* |  |

---

**Segment revenue from Mexico** decreased 12% YoY in 3Q25, explained by: (i) a slow recovery of volumes lost in 1Q25 due to legacy physician and supplier relationships, (ii) systems migration challenges during the implementation of a new Hospital Information system and ERP system at Doctors Hospital, which affected billing processes and are expected to stabilize in the coming months, (iii) continued market softness, reflected in low demand for emergency and surgical procedures, both key entry points for patient admissions into ICUs and hospitalizations, and, (iv) lower results in Auna Seguros (formerly Dentegra) compared to 3Q24. Auna continues to further expand the platform of doctors and their offerings, and has rebalanced the pricing mix for their services across the network to be more attractive to the payor base. While demand for surgeries fell 8% compared to 3Q24, the number of surgeries increased 5% in 2Q25 versus 1Q25 and 6% in 3Q25 versus 2Q25. Revenues from other high-complexity service lines — including radiotherapy, chemotherapy, and cardiology services — represented approximately 15% of Healthcare Network revenues and increased approximately 48% compared to 3Q24, offsetting declines in other services. Opción Oncología's growing momentum, with revenues up 21% from 2Q25, is an early validation of the AunaWay model in Mexico. Finally, 3Q25 capacity utilization modestly increased from 2Q25 to 39.1% of total capacity and 58.7% of operating capacity.

**Segment Adjusted EBITDA** decreased 29% YoY in 3Q25 and 14% from 2Q25, with a 3Q25 margin of 29.0%. The decline is explained in the healthcare network by lower revenue resulting in reduced gross profit, while contribution margins declined among certain payors. For example, at OCA — which serves state employee contracts — a higher mix of lower-margin procedures affected profitability. Mexico's Adjusted EBITDA Margin was 29.0%, a 6.9 p.p. decline from 3Q24 and a 3.0 p.p. decline from 2Q25.

**Update on Key Initiatives in Mexico**

While Auna's operations remained stable in Mexico during 3Q25, the Company implemented several initiatives aimed at further strengthening its healthcare network and improving operational and commercial execution across key business lines. Mexico continues to represent one of the largest and most underpenetrated private healthcare markets in Latin America, with growing demand for high-quality, integrated care. Auna's presence and its ongoing investments in technology, medical talent, and infrastructure position the Company to capture this long-term growth potential. These initiatives are also expected to support a return to growth in early 2026.

---

| | |
|:---|:---|
| **1-** | **Leadership and Organization** |

---

Auna continues to invest in talent in Mexico, appointing several local senior hires to key positions, including Alejandro Torres (formerly with Star Médica and TecSalud) as CEO of the Monterrey operations, a new Chief Medical Officer, a new Head of Commercial, and other senior leaders at the hospital levels. Collectively, these appointments bring over 100 years of combined experience in the Mexican healthcare market and are contributing to the ongoing standardization and integration of operational practices across Auna's facilities.

---

| | |
|:---|:---|
| **2-** | **Out-of-Pocket, Corporate Segments, and Institutional Packages** |

---

The Company is expanding its participation across three market segments through the development of packaged service offerings and closer collaboration with leading physicians to broaden its revenue base and increase capacity utilization: (i) Out-of-Pocket ("OOP"): OOP currently represents only 8% of revenue and Auna intends to increase this share to 20% by the end of 2026, in line with other key industry players, (ii) Corporate: Auna continues to develop new packages with corporate clients to offer additional services to their employees, and, (iii) Institutional packages: The Company is exploring tailored service packages for employees from surrounding municipalities and government entities in Monterrey.

---

| | |
|:---|:---|
| **3-** | **Physician Engagement and Productivity** |

---

Engagement with Auna's physician network and incentive models have resulted in a series of productivity and quality initiatives that are gaining momentum. The top 140 doctors, representing between 25% to 35% of revenues at each hospital are contributing to stronger alignment among physicians, payors, and suppliers to improve medical practices, operating performance, as well as cost predictability and control. In addition, the Company continues to attract and hire new medical and nursing talent in high-complexity areas.

---

| | |
|:---|:---|
| **4-** | **Payors** |

---

Auna is in active discussions with some of the largest insurance companies to expand participation within their preferred provider networks, which is expected to support increased patient access and service volumes across key healthcare facilities, beginning in 2026, and to increase capacity utilization.

---

| | |
|:---|:---|
| **5-** | **Oncology Business** |

---

On October 31, 2025, Auna held its second Oncology Congress in Monterrey, gathering more than 70 oncologists from across the country. On that day, the Company inaugurated a new OncoCenter at its Doctors Hospital facility, a Center of Excellence that offers oncology services within a single location, improving patient care and experience and integrated with the Company's regional network.

---

| | |
|:---|:---|
| **6-** | **IT System Implementations** |

---

As part of its integration, transformation, and efficiency initiatives in Mexico, Auna is implementing new comprehensive IT systems that will enhance the integration of financial and operational data, improving management visibility, cost control, and decision-making across healthcare facilities. The rollout at Doctors Hospital is expected to be completed in early 2026.

The above actions form part of Auna's broader strategy to strengthen its healthcare platform in Mexico, enhance patient care, drive sustainable operational improvements

across its facilities, and capture the significant long-term growth opportunity in the market.

**PERU OPERATIONS: HEALTHCARE SERVICES PERU AND ONCOSALUD PERU**

Auna's Healthcare Services and Oncosalud Peru accounted for 44% of consolidated revenues and 48% of consolidated Adjusted EBITDA.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Healthcare Services Peru and <br> Oncosalud Peru<br> Key Financial Metrics** | **3Q'25 (USD)** | **3Q'25** | **YTD 25** | **Δ 3Q'25 vs 3Q'24** | **Δ 3Q'25 vs 2Q'25** | **Δ YTD 25 vs YTD 24** |
| **Revenue** | **141** | **488** | **1423** | **9%** | **3%** | **9%** |
| *Healthcare Services Peru* | 80 | 279 | 812 | *9%* | *4%* | *8%* |
| *Oncosalud Peru* | 85 | 294 | 861 | *8%* | *3%* | *8%* |
| *Holding and Eliminations (\*)* |  | (84) | (249) | *6%* | *4%* | *5%* |
| **Consolidated Peru Adjusted EBITDA** | **32** | **111** | **314** | **15%** | **10%** | **14%** |
| *Healthcare Services Peru* | 13 | 44 | 119 | *14%* | *29%* | *3%* |
| *Oncosalud Peru* | 19 | 67 | 194 | *16%* | *1%* | *22%* |
| ***Consolidated Peru Adj. EBITDA margin*** *%*** |  | ***22.7%*** | ***22.0%*** | ***1.2 p.p.*** | ***1.5 p.p.*** | ***1.0 p.p.*** |
| *Healthcare Services Peru* |  | *15.7%* | *14.7%* | *0.6 p.p.* | *3.1 p.p.* | *-0.7 p.p.* |
| *Oncosalud Peru* |  | *22.9%* | *22.6%* | *1.6 p.p.* | *-0.5 p.p.* | *2.5 p.p.* |

---

(\*) Relates to intersegment revenue elimination.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Healthcare Services Peru<br> Key Operating Metrics** | | **3Q'25 (USD)** | **3Q'25** | **YTD 25** | **Δ 3Q'25 vs 3Q'24** | **Δ 3Q'25 vs 2Q'25** | **Δ YTD 25 vs YTD 24** |
| Beds | # |  | 385 | 385 | 3% | 0% | 3% |
| Surgeries | *# (000)* |  | 5.034 | 16 | -4% | -7% | 3% |
| Emergency treatments | *# (000)* |  | 49 | 135 | 3% | 3% | 1% |
| Operating capacity utilization | % |  | 78.0% | 75.9% | -7.1 p.p. | 2.4 p.p. | -7.5 p.p. |
| Total capacity utilization | % |  | 76.0% | 73.9% | 1.5 p.p. | 2.4 p.p. | 1.0 p.p. |
| **Key Financial Metrics** |  |  |  |  |  |  |  |
| Revenue |  | 80 | 279 | 812 | 9% | 4% | 8% |
| *External revenues* |  | 58 | *202* | *589* | 9% | 1% | 9% |
| *Intercompany revenue* |  | 22 | *77* | *222* | 11% | 12% | 6% |
| Segment Adjusted EBITDA |  | 13 | 44 | 119 | 14% | 29% | 3% |
| *Segment Adjusted EBITDA margin* | % |  | *15.7%* | *14.7%* | *0.6 p.p.* | *3.1 p.p.* | *-0.7 p.p.* |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Oncosalud Peru<br> Key Operating Metrics** | | **3Q'25 (USD)** | **3Q'25** | **YTD 25** | **Δ 3Q'25 vs 3Q'24** | **Δ YTD 25 vs YTD 24** |
| Plan memberships | *# (000)* |  | 1396 | 1396 | 8% | 8% |
| *Oncological Plans* | *# (000)* |  | *989* | *989* | 1% | 1% |
| Average monthly revenue per plan membership |  | 17.90 | 62.12 | 60.99 | 1% | 2% |
| Preventive check-ups | *# (000)* |  | 29 | 94 | 10% | 20% |
| Patients treated | *# (000)* |  | 12 | 65 | 40% | 24% |
| MLR | % |  |  | 54.5% |  | -3.1 p.p. |
| *Oncological Plans* | *%* |  |  | *49.3%* |  | *-4.4 p.p.* |
| **Key Financial Metrics** |  |  |  |  |  |  |
| Revenue |  | 85 | 294 | 861 | 8% | 8% |
| *External revenues* |  | *83* | *286* | *833* | *9%* | *9%* |
| *Intercompany revenue* |  | *2* | *7* | *27* | *-29%* | *-9%* |
| Segment Adjusted EBITDA |  | 19 | 67 | 194 | 16% | 22% |
| *Segment Adjusted EBITDA margin* | % |  | *22.9%* | *22.6%* | *1.6 p.p.* | *2.5 p.p.* |

---

**Total revenue from Peru** increased 9% YoY to S/488 million in 3Q25. The 8% YoY increase in revenues at the Oncosalud Peru segment reflects an 8% increase in total plan memberships, as well as the effect of annual price adjustments to support medical inflation in Oncology and Healthcare plans. Oncosalud's MLR decreased 3.1 p.p. to 54.5%, led by the Oncology MLR, which decreased for a fifth consecutive quarter to 49.3%, or 4.4 p.p.

The Healthcare Services segment increased revenues by 9% YoY, reflecting an increase in revenues from emergency visits and ambulatory care, including for chemotherapy services, and driven by ticket and quantity of services, more than offsetting a slight decrease in surgery volumes as well as in hospitalization revenues.

Additionally, Auna updated the number of operating beds at Clínica Delgado, Clínica Vallesur and Clínica Miraflores in Piura, and increased a total of 10 beds to total capacity. As a result, operating capacity utilization was 78.0%, and the total capacity utilization was 76.0%.

Our Peruvian operations continue to have substantial opportunity ahead and will remain a key contributor to Auna's performance.

**Consolidated Adjusted EBITDA in Peru** increased 15% YoY to S/111 million in 3Q25, with a margin of 22.7%, an increase of 1.2 p.p. from 3Q24.

The growth in Consolidated Adjusted EBITDA in Peru was primarily driven by an increase in gross profit resulting from efficiencies in pharmaceutical costs at Oncosalud and lower costs related to surgical procedures, partially offset by an increase in SG&A to support the growth of the Peruvian operations, including sales commissions, expenses related to medical and administrative staff retention, and third-party medical services.

**HEALTHCARE SERVICES COLOMBIA**

*(Explanations of variances are in local currency unless expressed otherwise)*

Auna's Healthcare services operations in Colombia accounted for 33% of consolidated revenues and 22% of consolidated Adjusted EBITDA.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| |  | | | | **Δ 3Q'25 vs 3Q'24** | **Δ 3Q'25 vs 3Q'24** | **Δ 3Q'25 vs 2Q'25** | **Δ 3Q'25 vs 2Q'25** | **Δ YTD 25 vs YTD 24** | **Δ YTD 25 vs YTD 24** |
| <br>**Healthcare Services Colombia<br> Key Operating Metrics** | | <br>**3Q'25 (USD)** | <br>**3Q'25** | <br>**YTD 25** | **As Reported** | **L.C.** | **As Reported** | **L.C.** | **As Reported** | **L.C.** |
| Beds | # |  | 1131 | 1131 | 1% |  | 0% |  | 1% |  |
| Surgeries | *# (000)* |  | 11 | 32 | -9% |  | 7% |  | -10% |  |
| Emergency treatments | *# (000)* |  | 37 | 110 | -14% |  | 4% |  | -4% |  |
| Operating capacity utilization | % |  | 86.5% | 86.1% | -3.6 p.p |  | 1.0 p.p |  | -2.9 p.p |  |
| Total capacity utilization | % |  | 77.1% | 76.8% | -5.2 p.p |  | 0.7 p.p |  | -4.5 p.p |  |
| **Key Financial Metrics** |  |  |  |  |  |  |  |  |  |  |
| Segment Revenue |  | 106 | 369 | 1054 | 1% | 4% | 6% | 4% | -3% | 3% |
| Segment Adjusted EBITDA |  | 15 | 51 | 150 | 14% | 18% | -12% | -13% | -1% | 6% |
| *Segment Adjusted EBITDA margin* | *%* |  | *13.9%* | *14.3%* | *1.5 p.p* |  | *-2.8 p.p* |  | *0.3 p.p.* |  |

---

**Segment revenue from Colombia** in 3Q25 grew 4% YoY, primarily due to the gradual implementation of risk-sharing models in Antioquia and Monteria, including PGPs for cardiovascular, ambulatory, and oncology services. Revenue growth was also due to higher surgery tickets, which offset revenue declines related to lower volumes that resulted from Auna limiting surgeries as part of its strategy to manage revenues and cashflows from government-intervened payors. Specifically, the share of revenues from payor Nueva EPS decreased from 20% in 3Q24 to 13% in 3Q25. During the quarter, Auna also added Salud Total as a new payor under a PGP contract, further diversifying the payor base; through these initiatives, PGP revenues accounted for 18% of Colombia's total revenues in 3Q25, increasing from 14% in 3Q24. Additional contributions to the top line came from continued growth in chemotherapy and imaging services.

Operating capacity utilization in Colombia was 86.5%, a YoY decrease of 3.6 p.p., while total capacity utilization decreased 5.2 p.p. to 77.1% from 3Q24, both in line with the aforementioned strategy to proactively manage contracted services with government-intervened payors to prioritize cash generation over revenue growth.

**Segment Adjusted EBITDA** increased 18% YoY in 3Q25, with the margin expanding 1.7 p.p. to 13.9%. The increase was related to revenue growth, partially offset by increases in doctor remuneration, and to lower impairment losses. These losses were S/2 million in 3Q25 compared to S/16 million in 3Q24.

Balance Sheet & Cash Flow

**Consolidated Debt** 

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Sep-25 (USD)** | **Sep-25** | **Dec-24** | **Sep-24** | **Δ Sep-25 vs** | **Δ Sep-25 vs** |
|  | **Sep-25 (USD)** | **Sep-25** | **Dec-24** | **Sep-24** | **Sep-24** | **Dec-24** |
| &nbsp;&nbsp;&nbsp;(+) Loans and borrowings | 1016 | 3526 | 3620 | 3602 | -2% | -3% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Short term debt* | *190* | *658* | *654* | *582* | 13% | 1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Long term debt* | *826* | *2868* | *2966* | *3021* | -5% | -3% |
| &nbsp;&nbsp;&nbsp;(+) Lease Liabilities | 37 | 129 | 148 | 139 | -7% | -13% |
| **Gross Debt** | **1053** | **3655** | **3768** | **3741** | **-2%** | **-3%** |
| &nbsp;&nbsp;&nbsp;(-) Cash and cash equivalents / marketable securities | 65 | 226 | 236 | 200 | 13% | -4% |
| **Net Debt** | **988** | **3429** | **3532** | **3541** | **-3.2%** | **-2.9%** |
| **Leverage Ratio** |  | **3.6x** | **3.6x** | **3.7x** | **-0.1x** | **0.1x** |

---

**Gross Debt** at the close of 3Q25 decreased 3% versus 4Q24 to S/3,655 million, due to: (i) a S/82 million decrease due to FX, mainly driven by an 8% appreciation of the PEN/USD exchange rate, (ii) a S/234 million reduction due to a partial amortization of the credit agreement dated November 10, 2023 (the "Credit Agreement"), (iii) a S/47 million reduction of long-term debt and financial and operating leasing, partially offset by (iv) a S/19 million increase in short-term debt due to working capital needs, and (v) an increase of S/230 million in long-term debt, mainly related to the May 2025 issuance of additional 10% Senior Secured Notes due 2029 (the "2029 Notes").

**Leverage Ratio** was 3.6x unchanged at the end of 3Q25 compared to year-end 2024. This reflects lower gross debt offset by lower LTM EBITDA versus 4Q24, due to FX impacts and less cash at the end of the period. Auna remains committed to a medium-term leverage target of less than 3.0x.

On November 6, 2025, the Company successfully completed a refinancing of debt for a total of USD765 million backed by its relationship banks, institutional investors and the IFC. The new 8.75% Senior Secured Notes were issued at par for USD365 million in aggregate principal amount and will mature on November 6, 2032. The Company also closed on a new USD400 million equivalent MXN Term Loan (the "Term Loan") maturing on October 15, 2030. The Term Loan also contains an incremental USD60 million equivalent tranche in Peruvian Soles that the Company expects to disburse in the near term. The above proceeds were used to fund a tender offer conducted by the Company to purchase for cash any or all of its 2029 Notes, to prepay indebtedness under the Credit Agreement, to pay related interest, fees and expenses, and to repay other short-term debt.

**Consolidated Debt Amortization Profile Prior to the USD765 million Refinancing**

*(Figures in millions of Soles, unless expressed otherwise)*

 

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Total** | **Leases** | **Y1** | **Y2** | **Y3** | **Y4** | **Y5** | **Y6+** |
| Loans and Borrowings | 3526 |  | 663 | 334 | 566 | 592 | 1322 | 47 |
| Financial Leases | 51 |  | 15 | 20 | 5 | 3 | 3 | 6 |
| Operating Leases | 78 | 78 | 0 | 0 | 0 | 0 | 0 | 0 |
| **Gross Debt** | **3655** | **78** | **679** | **354** | **571** | **595** | **1325** | **53** |

---

As of 3Q25. Excludes interest. Reflects figures post-refinancing. Y1 = October 2025 to September 2026, Y2 = October 2026 to September 2027, Y3 = October 2027 to September 2028, Y4 = October 2028 to September 2029, Y5 = October 2029 to September 2030, and Y6+ = October 2030 to September 2035.

**Cashflow and Cash Conversion Cycle**

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **YTD 25 (USD)** | **YTD 25** | **YTD 24** | **Δ YTD 25 vs YTD 24** |
| **Net cash from operating activities** | **127** | **440** | **475** | **-7%** |
| **Net cash used in investing activities** | **(34)** | **(119)** | **(173)** | **-31%** |
| **Net cash used in financing activities** | **(97)** | **(336)** | **(328)** | **3%** |
| **Cash and cash equivalents at the end of the period** | **65** | **226** | **200** | **13%** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **LTM Sep-24** | **LTM Jun-25** | **LTM Sep-25** |
| Days Sales Outstanding | 81 | 87 | 89 |
| Days Inventory Outstanding | 38 | 41 | 42 |
| Days Payable Outstanding | 116 | 132 | 132 |
| **Cash Conversion Cycle** | **4** | **-3** | **0** |
| \*Measured on an average basis according to last twelve months results. | \*Measured on an average basis according to last twelve months results. | \*Measured on an average basis according to last twelve months results. | \*Measured on an average basis according to last twelve months results. |

---

Net cash from operating activities decreased 7% YoY, or S/35 million, to S/440 million for the nine months ended September 30, 2025 versus the comparable period last year, and included: (i) a S/30 million decrease in cash generated from operating activities, including S/12 million in performance-based bonuses to Opción Oncología doctors and the impacts on the billing cycle during the information systems transition in Mexico, which are expected to stabilize in the coming months, and (ii) a S/3 million decrease in net interest received, partially offset by a S/2 million decrease in income taxes paid. The migration to new information systems in Mexico added a two- day increase in sales outstanding when compared to LTM June 2025.

Net cash used in investing activities decreased 31% YoY, or S/54 million, to S/119 million for the nine months ended September 30, 2025 versus the comparable period last year,

and included: (i) S/98 million in organic maintenance CapEx, including an S/8 million payment for branding rights to Opción Oncología doctors, (ii) a S/15 million payment to former OCA shareholders for holdback obligations, and, (iii) a S/6 million earnout payment to IMAT Oncomedica shareholders. In the nine months ended September 30, 2024, investing activities included: (i) S/109 million in organic maintenance CapEx, (ii) a S/47 million earnout payment to IMAT Oncomedica shareholders, and iii) a S/18 million payment to OCA shareholders.

Net cash used in financing activities was S/336 million, an increase of 3% YoY, or S/8 million, for the nine months ended September 30, 2025 versus the comparable period last year. Cash used in financing activities during the period included: (i) S/163 million in term loan interest payments, (ii) S/26 million for hedge premium and swap interest payments, (iii) S/58 million in interest for the 2029 Notes, (iv) S/50 million in interest payments for working capital facilities, and (v) a S/39 million reduction in working capital borrowings. The comparable nine months ended September 30, 2024 period included: (i) S/212 million in Credit Agreement interest payments, (ii) S/36 million for hedge premiums, (iii) S/55 million in interest payments for the 2029 Notes and 2025 Senior Unsecured Notes, (iv) S/51 million in interest payments for working capital facilities, (v) S/9 million in additional working capital borrowings, and (vi) S/18 million in IPO proceeds and related refinancing activities as well as the repayment of certain indebtedness and financial obligations following the IPO.

Recent Developments

**Auna Announces Strategic Collaboration with Sojitz to Expand Healthcare Access in Latin America**

Auna and Sojitz Corporation of America ("Sojitz"), a global investment and trading group headquartered in Japan, have entered into a Memorandum of Understanding to explore joint business opportunities in the healthcare sector across Latin America, with an initial focus on Mexico, one of the region's largest and fastest-growing healthcare markets.

On September 24, 2025, Auna announced its intention to invest approximately US$500 million over the next three to five years to expand its integrated healthcare platform in Mexico.

The collaboration seeks to combine Auna's healthcare and operational expertise with Sojitz's investment capabilities in healthcare and international network to accelerate the development of modern, scalable, and accessible healthcare infrastructure and services in Latin America.

**Construction License for Torre Trecca Is Delivered to EsSalud, Marking a Key Milestone in Auna's Public–Private Partnership with the Institution**

On November 18, Auna announced that EsSalud formally received the construction license for Torre Trecca, an outpatient high-rise treatment center that Auna will rebuild and operate on behalf of EsSalud under the existing public–private partnership. Once completed, Torre Trecca is expected to serve the more than 6 million Peruvians living in Lima who are insured by EsSalud and to accommodate in excess of 3 million patient visits per year.

**About AUNA**

Auna is a leading healthcare platform in Latin America with operations in Mexico, Peru, and Colombia, prioritizing prevention and concentrating on high-complexity diseases that contribute the most to healthcare expenditures. Our mission is to transform healthcare by providing access to a highly integrated healthcare offering in the underpenetrated markets of Spanish-Speaking Americas. Founded in 1989, Auna has built one of Latin America's largest modern healthcare platforms that consists of a horizontally integrated network of healthcare facilities and a vertically integrated portfolio of oncological plans and selected general healthcare plans. As of September 30, 2025, Auna's network included 31 healthcare network facilities, consisting of hospitals, outpatient, prevention and wellness facilities with a total of 2,333 beds, and 1.4 million healthcare plans.

For more information visit www.aunainvestors.com

Conference Call Details

**When:** 8:00 a.m. Eastern time, Nov 21, 2025

**Who:** Mr. Suso Zamora, Executive Chairman of the Board and President; Mrs. Gisele Remy, Chief Financial Officer and Executive Vice President; Mr. Lorenzo Massart, Executive Vice President of Strategy and Equity Capital Markets.

**Dial-in:** +1 888 596 4144 (U.S. domestic), +1 646 968 2525 (International)<br> **Passcode:** 3884034

To access Auna's financial results call via telephone, callers need to press # to be connected to an operator.

**Webcast:** <u>https://events.q4inc.com/attendee/509204255</u>

**Definitions and Concepts**

Figures in US dollars (US$ or USD) for 3Q25 are presented for indicative purposes and were calculated using an FX rate of US$1= S/3.470. All comparisons in this announcement are

year-over-year ("YoY"), unless otherwise noted; additionally, results are presented in an FX neutral basis ("FXN") for consolidated revenues, consolidated cost of sales and services, consolidated selling and administrative expenses and consolidated adjusted EBITDA, as well as, in local currency for the Mexico and Colombia segments, to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods.

Financial results are preliminary and subject to year-end audit.

**Use of Non-IFRS Financial Measures**

This release includes financial measures defined as "non-IFRS financial measures" by the SEC, including: EBITDA, EBITDA Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted LTM EBITDA, Segment EBITDA, Segment EBITDA Margin, Segment Adjusted EBITDA, Segment Adjusted EBITDA Margin, Consolidated Peru Adjusted EBITDA, Consolidated Peru Adjusted EBITDA Margin, Adjusted Net Income, Adjusted Net Income, Basic and Diluted EPS, Adjusted Basic and Diluted EPS, Leverage Ratio and FX Neutral because we believe they assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance.

In addition, management and our board of directors use these non-IFRS financial measures to assess our financial performance and believe they are helpful in highlighting trends in our core operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding the growth of our business. These are not measures of operating performance under IFRS and have limitations as analytical tools. You should not consider such measures either in isolation or as substitutes for analyzing our results as reported under IFRS. Additionally, our calculations of EBITDA, Segment EBITDA, Adjusted EBITDA, Adjusted Net Income, EBITDA Margin, Adjusted EBITDA Margin, Adjusted Net Income Margin, FX Neutral and Leverage Ratio may be different from the calculations used by other companies for similarly titled measures, including our competitors, and therefore may not be comparable to those of other companies.

**EBITDA:** is calculated as profit (loss) before tax for the period plus net finance cost and depreciation and amortization. EBITDA is a key metric used by management and our board of directors to assess our financial performance.

**EBITDA Margin:** is calculated as EBITDA divided by total revenue from contracts with customers.

**Adjusted EBITDA:** is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

**Adjusted EBITDA Margin:** is calculated as Adjusted EBITDA divided by total revenue from contracts with customers.

**Adjusted Last Twelve Month ("LTM") EBITDA**: is calculated by adding the last four quarters beginning with the corresponding period.

**Segment EBITDA:** is calculated as segment profit before tax plus net finance cost and depreciation and amortization.

**Segment EBITDA Margin:** is calculated as segment EBITDA divided by total segment revenue from contracts with customers.

**Segment Adjusted EBITDA:** is calculated as segment profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre-operating expenses for projects under construction, business development (income) expenses for expansion into new markets, change in fair value of earn-out liabilities, stock-based consideration and personnel non-recurring compensation.

**Segment Adjusted EBITDA Margin**: is calculated as segment Adjusted EBITDA divided by total Segment revenue from contracts with customers.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **3Q'25 (USD)** | | | **Δ 3Q'25 vs** | **Δ 3Q'25 vs** | **Δ YTD 25 vs** |
|  | **3Q'25 (USD)** | <br>**3Q'25** | <br>**YTD 25** | **3Q'24** | **2Q'25** | **YTD 24** |
| **Revenues** |  | **1117** | **3253** | **-1%** | **2%** | **-2%** |
| **Profit (Loss) before Tax** | **28** | **97** | **291** | **-24%** | **-27%** | **98%** |
| (+) Net Finance Cost | 21 | 72 | 199 | -31% | 54% | -56% |
| (+) Depreciation and Amortization | 17 | 57 | 166 | 4% | 4% | -1% |
| **(=) EBITDA** | **65** | **226** | **655** | **-21%** | **-4%** | **-15%** |
| (+) Adjustments | 1.9 | 6.6 | 40.9 |  |  |  |
| &nbsp;&nbsp;&nbsp;*(a) Pre-operating expenses* | -0.1 | *-0.3* | *0.4* |  |  |  |
| &nbsp;&nbsp;&nbsp;*(b) Business development expenses* | 1.1 | *3.8* | *31.5* |  |  |  |
| &nbsp;&nbsp;&nbsp;*(c) Stock-based consideration* | 0.9 | *3.0* | *8.3* |  |  |  |
| &nbsp;&nbsp;&nbsp;*(d) Personnel non-recurring compensation* | *0.0* | *0.0* | *0.6* |  |  |  |
| **(=) Adjusted EBITDA** | **67** | **232** | **696** | **-7%** | **-4%** | **-6%** |
| *Adjusted EBITDA Margin* |  | *20.8%* | *21.4%* | *-1.3 p.p.* | *-1.2 p.p.* | *-0.8 p.p.* |

---

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Torre Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended September 30, 2025** | **For the three months ended September 30, 2025** | **For the three months ended September 30, 2025** | **For the three months ended September 30, 2025** | **For the three months ended September 30, 2025** | **For the three months ended September 30, 2025** | **For the three months ended September 30, 2025** |
|  | **Healthcare Services Mexico** | **Healthcare Services Peru** | **Oncosalud Peru** | **Healthcare Services Colombia** | **Holding and eliminations** | **Consolidated Reportable Segments** |
| **Revenues** | **264** | **279** | **294** | **369** | **(88)** | **1117** |
| **Profit (Loss) before Tax** | **21** | **20** | **54** | **33** | **(31)** | **97** |
| (+) Net Finance Cost | 33 | 9 | 3 | 6 | 21 | 72 |
| (+) Depreciation and Amortization | 22 | 12 | 9 | 11 | 3 | 57 |
| **(=) Segment EBITDA** | **76** | **42** | **65** | **49** | **(7)** | **226** |
| (+) Adjustments | 0.9 | 1.8 | 1.8 | 1.8 | 0.3 | 6.6 |
| Pre-operating expenses | *0.0* | *0.0* | *0.0* | *0.0* | *-0.3* | *-0.3* |
| Business development expenses | *-1.0* | *1.6* | *1.6* | *1.7* | *0.0* | *3.8* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *1.9* | *0.2* | *0.2* | *0.1* | *0.6* | *3.0* |
| Personnel non-recurring compensation | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| **(=) Segment Adjusted EBITDA** | **77** | **44** | **67** | **51** | **-6** | **232** |
| Adjusted EBITDA Margin | 29.0% | 15.7% | 22.9% | 13.9% |  | 20.8% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **For the three months ended September 30, 2024** | **For the three months ended September 30, 2024** | **For the three months ended September 30, 2024** | **For the three months ended September 30, 2024** | **For the three months ended September 30, 2024** | | |
|  | **Healthcare Services Mexico** | **Healthcare Services Peru** | **Oncosalud Peru** | **Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Revenues** | **316** | **255** | **273** | **363** | **(80)** | **1127** |
| **Profit (Loss) before Tax** | **69** | **20** | **45** | **5** | **(11)** | **127** |
| (+) Net Finance Cost | 66 | 7 | 5 | 29 | (3) | 103 |
| (+) Depreciation and Amortization | 23 | 11 | 8 | 11 | 2 | 55 |
| **(=) Segment EBITDA** | **157** | **37** | **58** | **44** | **(11)** | **286** |
| (+) Adjustments | (43.9) | 1.2 | 0.0 | 0.7 | 5.8 | (36.2) |
| Pre-operating expenses | *0.0* | *0.0* | *0.0* | *0.0* | *0.1* | *0.1* |
| Business development expenses | *-43.9* | *0.0* | *0.0* | *0.0* | *0.0* | *-43.9* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *0.0* | *0.0* | *0.0* | *0.0* | *5.7* | *5.7* |
| Personnel non-recurring compensation | *0.0* | *1.2* | *0.0* | *0.7* | *0.0* | *1.9* |
| **(=) Segment Adjusted EBITDA** | **113** | **38** | **58** | **45** | **(6)** | **250** |
| Adjusted EBITDA Margin | 35.9% | 15.1% | 21.3% | 12.4% |  | 22.1% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Year to date September 30, 2025** | **Year to date September 30, 2025** | **Year to date September 30, 2025** | **Year to date September 30, 2025** | | | |
|  | **Healthcare Services Mexico** | **Healthcare Services Peru** | **Oncosalud Peru** | <br>**Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Revenues** | **781** | **812** | **861** | **1054** | **(253)** | **3253** |
| **Profit (Loss) before Tax** | **41** | **54** | **152** | **105** | **(62)** | **291** |
| (+) Net Finance Cost | 106 | 27 | 13 | 13 | 39 | 199 |
| (+) Depreciation and Amortization | 65 | 36 | 27 | 31 | 8 | 166 |
| **(=) Segment EBITDA** | **212** | **117** | **192** | **148** | **(15)** | **655** |
| (+) Adjustments | 32.5 | 2.1 | 2.1 | 1.9 | 2.2 | 40.9 |
| Pre-operating expenses | *0.0* | *0.0* | *0.0* | *0.0* | *0.4* | *0.4* |
| Business development expenses | *26.6* | *1.6* | *1.6* | *1.7* | *0.0* | *31.5* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *5.3* | *0.5* | *0.5* | *0.2* | *1.8* | *8.3* |
| Personnel non-recurring compensation | *0.6* | *0.0* | *0.0* | *0.0* | *0.0* | *0.6* |
| **(=) Segment Adjusted EBITDA** | **245** | **119** | **194** | **150** | **-13** | **696** |
| Adjusted EBITDA Margin | 31.4% | 14.7% | 22.6% | 14.3% |  | 21.4% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Year to date September 30, 2024** | **Year to date September 30, 2024** | **Year to date September 30, 2024** | | | | |
|  | **Healthcare Services Mexico** | **Healthcare Services Peru** | <br>**Oncosalud Peru** | <br>**Healthcare Services Colombia** | <br>**Holding and eliminations** | <br>**Consolidated Reportable Segments** |
| **Revenues** | **927** | **751** | **795** | **1090** | **(239)** | **3323** |
| **Profit (Loss) before Tax** | **47** | **46** | **119** | **(5)** | **(61)** | **146** |
| (+) Net Finance Cost | 236 | 35 | 17 | 124 | 41 | 454 |
| (+) Depreciation and Amortization | 73 | 31 | 24 | 32 | 7 | 167 |
| **(=) Segment EBITDA** | **356** | **113** | **160** | **152** | **(13)** | **767** |
| (+) Adjustments | (38.6) | 2.8 | 0.0 | 0.7 | 6.6 | (28.5) |
| Pre-operating expenses | *1.9* | *0.0* | *0.0* | *0.0* | *0.3* | *2.3* |
| Business development expenses | *-42.5* | *0.0* | *0.0* | *0.0* | *0.0* | *-42.5* |
| Change in fair value of earn-out liabilities | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* | *0.0* |
| Stock-based consideration | *0.0* | *0.0* | *0.0* | *0.0* | *6.3* | *6.3* |
| Personnel non-recurring compensation | *2.0* | *2.8* | *0.0* | *0.7* | *0.0* | *5.5* |
| **(=) Segment Adjusted EBITDA** | **317** | **116** | **160** | **153** | **-7** | **739** |
| Adjusted EBITDA Margin | 34.2% | 15.4% | 20.1% | 14.0% |  | 22.2% |

---

**Consolidated Peru Adjusted EBITDA:** is calculated by adding Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA.

**Consolidated Peru Adjusted EBITDA Margin**: is calculated as Healthcare Services Peru segment Adjusted EBITDA plus Oncosalud Peru segment Adjusted EBITDA, divided by total revenues from Healthcare Services Peru Segment plus total revenues from Oncosalud Peru segment.

**Adjusted Net Income:** is calculated as profit (loss) for the period plus adjustments as described below.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **3Q'25 (USD)** | **3Q'25** | **3Q'24** | **YTD 25** | **YTD 24** |
| <br>**Net Income (Loss)** | **15** | **53** | **101** | **175** | **100** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(a) Pre-operating expenses* | (0.1) | (0.3) | 0.1 | 0.4 | 2.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(b) Business development expenses* | 1.1 | 3.8 | (43.9) | 31.5 | (42.5) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(c) Stock-based consideration* | 0.9 | 3.0 | 5.7 | 8.3 | 6.3 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(d) Personnel non-recurring compensation* | 0.0 | 0.0 | 1.9 | 0.6 | 5.5 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(e) Non-cash and non-recurring financial costs* | 0.3 | 1.1 | 0.0 | 1.1 | 29.6 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*(f) Allocated tax effects* | (0.9) | (3.0) | 11.0 | (16.0) | 8.7 |
| **(=) Adjusted Net Income** | **17** | **58** | **75** | **201** | **110** |

---

(a) Pre-operating expenses consist of legal and administrative expenses incurred in connection with medical facilities under construction, such as Clínica Chiclayo, costs relating to the Torre Trecca PPP, and legal and administrative expenses incurred in connection with the acquisition of land banks for future facilities.

(b) Business development expenses consist of expenses incurred in connection with projects and payments to sellers to expand into new markets, including through greenfield projects and M&A activity.

(c) Stock-based consideration includes share-based payments plans for non-executive members of the Board of Directors and other Auna management including executives and employees.

(d) Personnel non-recurring compensation related to the implementation of an efficiency program across business units aimed at streamlining processes and capturing synergies on the local and regional levels.

(e) Non-cash and non-recurring financial costs include; 1) one-time non-recurring costs of refinancing activities; 2) non-cash derivative costs related to mark to market of legacy derivatives related to extinguished financings; 3) non-cash effects related to early extinguishment of financings, and 4) non-cash effects related to the accounting impact of changes in the fair value of the liability for mandatory purchase of shares from IMAT.

(f) Allocated tax effects neutralize the tax shield that the items considered as adjustment have generated in the taxable profit.

**Basic and Diluted Earnings per Share:** Basic and Diluted Earnings per Share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

**Adjusted Basic and Diluted Earnings per Share:** Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Income of the Company by the weighted average number of basic and diluted shares outstanding during the period, which excludes treasury shares.

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **3Q'25 (USD)** | **3Q'25** | **3Q'24** | **YTD 25** | **YTD 24** |
| <br>**Net Income (Loss)** | **15** | **53** | **101** | **175** | **100** |
| *Income (Loss) attributable to Owner of the company* | *14* | *48* | *98* | *166* | *88* |
| *Weighted average number of basic and diluted shares at September 30* |  | *74.2* | *74.2* | *74.2* | *65.3* |
| ***Basic and diluted earnings per share*** | **0.19** | **0.65** | **1.32** | **2.23** | **1.35** |
| **Adjusted Net Income (Loss)** | **17** | **58** | **75** | **201** | **110** |
| *Income (Loss) attributable to owners of Adjusted Net Income* | *15* | *53* | *73* | *191* | *98* |
| *Weighted average number of basic and diluted shares at September 30* |  | *74.2* | *74.2* | *74.2* | *65.3* |
| ***Adjusted Basic and Diluted Earnings per Share*** | **0.20** | **0.71** | **0.98** | **2.58** | **1.50** |

---

**Leverage Ratio:** We calculate Leverage Ratio as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted EBITDA.

*(Figures in millions of Soles, unless expressed otherwise)*

---

| | | | |
|:---|:---|:---|:---|
|  | **Sep-24** | **Dec-24** | **Sep-25** |
|  | **Sep-24** | **Dec-24** | **Sep-25** |
| Current and non-current loans & borrowings | 3602 | 3620 | 3526 |
| Current and non-current lease liabilities | 139 | 148 | 129 |
| Cash and cash equivalents | 200 | 236 | 226 |
| Net Debt | 3541 | 3532 | 3429 |
| Adjusted LTM EBITDA | 952 | 993 | 951 |
| **Leverage Ratio** | **3.7x** | **3.6x** | **3.6x** |

---

 

**Net Debt:** We calculate Net Debt as Gross Debt minus Cash and cash equivalents.

*(Figures in millions of Soles, unless expressed otherwise)*

---

| | | | |
|:---|:---|:---|:---|
|  | **Sep-24** | **Dec-24** | **Sep-25** |
|  | **Sep-24** | **Dec-24** | **Sep-25** |
| (+) Loans and borrowings | 3602 | 3620 | 3526 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Short term debt* | *582* | *654* | *658* |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*Long term debt* | *3021* | *2966* | *2868* |
| (+) Lease Liabilities | 139 | 148 | 129 |
| **Gross Debt** | **3741** | **3768** | **3655** |
| &nbsp;&nbsp;&nbsp;(-) Cash and cash equivalents | 200 | 236 | 226 |
| **Net Debt** | **3541** | **3532** | **3429** |

---

**FX Neutral:** FX Neutral ("FXN") measures are prepared and presented to eliminate the effect of foreign exchange, or "FX," volatility between the comparison periods, allowing management and investors to evaluate financial performance despite variations in foreign currency exchange rates, which may not be indicative of core operating results and business outlook.

FX Neutral measures are presented because management believes that these non-IFRS financial measures can provide useful information to investors, securities analysts and the public in their review of operating and financial performance, although they are not calculated in accordance with IFRS or any other generally accepted accounting principles and should not be considered as a measure of performance in isolation.

The FX Neutral measures were calculated to present what such measures in preceding periods would have been had exchange rates remained stable from these preceding periods until the date of the Company's most recent financial information.

The FX Neutral measures for the three months ended September 30, 2024 were calculated by multiplying the as reported amounts of Revenue, Adjusted EBITDA and the key business metrics for such period by the average Mexican pesos / Peruvian soles exchange rate for the three months ended September 30, 2024 (MXN 5.0339 to PEN 1.00) and the average Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2024 (COP 1,089.2663 to PEN 1.00); then using such results to re-translate the corresponding amounts back to Peruvian soles by dividing them by the

average Mexican pesos / Peruvian soles and Colombian pesos / Peruvian soles exchange rate for the three months ended September 30, 2025 (MXN 5.2713 to PEN 1.00 / COP 1,131.3043 to PEN 1.00), so as to present what certain of statement of profit and loss amounts and key business metrics would have been had exchange rates remained stable from this past period until the three months ended September 30, 2025.

**Safe Harbor Statement**

This press release contains forward-looking statements. Forward-looking statements convey our current expectations or forecasts of future events. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to differ materially from the forward-looking statements that we make. Forward-looking statements typically are identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "project," "plan," "believe," "potential," "continue," "is/are likely to," or other similar expressions. Forward-looking statements that appear in a number of places in this press release include, but are not limited to, statements regarding the intent, belief or current expectations, regarding various matters, including, our target Leverage Ratio, the expected resolution of the issues with physicians, suppliers and information systems in Mexico, the results of the key initiatives we are implementing in Mexico, the expected capacity and market of Torre Trecca once built, the execution of our strategic plan, including the recovery of our growth levels and the roll-out of the AunaWay in Mexico, our collaboration with Sojitz, our planned investments in Mexico and the creation of further growth and sustainable value for all stakeholders. Any or all of our forward-looking statements in this press release may turn out to be inaccurate. Our actual results could differ materially from those contained in forward-looking statements due to a number of factors.

The forward-looking statements in this press release represent our expectations and forecasts as of the date of this press release. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. For a discussion of the risks facing the Company which could affect whether these forward-looking statements are realized, see our Form 20-F filing with the U.S. Securities and Exchange Commission (the "SEC").

**Financial Guidance Disclaimer**

Auna's guidance is based on management's current performance outlook and expected macroeconomic and regulatory conditions in the three countries where the Company operates. Any changes in these conditions could have an impact on the guidance provided.

Auna's financial guidance reflects management's current assumptions regarding numerous evolving factors that are difficult to accurately predict, including those discussed in the Risk Factors set forth in the Company's Form 20-F filed with the SEC. Reconciliations of forward-looking non-IFRS measures, specifically Leverage Ratio guidance, to the relevant forward-looking IFRS measures are not being provided, as the

Company does not currently have sufficient data to accurately estimate the variables and individual adjustments for such guidance and reconciliations. Due to this uncertainty, the Company cannot reconcile projected Leverage Ratio to projected net income without unreasonable effort. The financial guidance constitutes forward-looking statements. For more information, see the "Forward-Looking Statements" section in this release.

**IR Contact** 

Email: contact@aunainvestors.com

- Financial Tables Follow –

**Balance Sheet (1/2)**

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Sep-25 (USD)** | **Sep-25** | **Dec-24** | **Δ Sep-25 vs Dec-24** |
| **Assets** |  |  |  |  |
| Current assets |  |  |  |  |
| Cash and cash equivalents | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;226 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;236 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10) |
| Trade accounts receivable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;310 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1076 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;962 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;114 |
| Other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;74 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;256 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;253 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Inventories | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;43 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;149 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;144 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9) |
| Other investments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| **Total current assets** | **520** | **1806** | **1704** | **102** |
| **Non-current assets** |  |  |  |  |
| Trade accounts receivable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| Other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Investments in associates and joint venture | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 |
| Property furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;664 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2304 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2280 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24 |
| Intangible assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;788 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2734 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2657 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77 |
| Right-of-use assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;116 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;131 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15) |
| Investment properties | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) |
| Deferred tax assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;64 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;221 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;194 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 |
| Other investments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 |
| **Total non-current assets** | **1578** | **5476** | **5377** | **99** |
| **Total assets** | **2099** | **7282** | **7081** | **201** |

---

**Balance Sheet (2/2)**

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Sep-25 (USD)** | **Sep-25** | **Dec-24** | **Δ Sep-25 vs Dec-24** |
| **Liabilities** |  |  |  |  |
| **Current liabilities** |  |  |  |  |
| Loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;190 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;658 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;654 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 |
| Lease liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Trade accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;273 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;946 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;931 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 |
| Other accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;92 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;321 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;290 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31 |
| Provisions | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23 |
| Insurance contract liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Deferred income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| **Total current liabilities** | **580** | **2014** | **1945** | **69** |
| **Non-current liabilities** |  |  |  |  |
| Loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;826 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2868 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2966 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(98) |
| Lease liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;98 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;115 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18) |
| Trade accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Other accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;134 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;73 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;61 |
| Derivative financial instruments | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;41 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;27 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14 |
| Deferred tax liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;89 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;310 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;328 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18) |
| Deferred income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| **Total non-current liabilities** | **995** | **3453** | **3513** | **(60)** |
| **Total liabilities** | **1575** | **5467** | **5458** | **9** |
| **Total equity** | **523** | **1815** | **1623** | **192** |
| **Total liabilities and equity** | **2099** | **7282** | **7081** | **201** |

---

**Income Statement** 

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **3Q'25 (USD)** | **3Q'25** | **YTD 25** | | |
|  | **3Q'25 (USD)** | **3Q'25** | **YTD 25** | **Δ 3Q'25 vs**<br>**3Q'24** | **Δ YTD 25 vs**<br>**YTD 24** |
| **Revenue** |  |  |  |  |  |
| Healthcare Services Mexico | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;264 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;781 | -16% | -16% |
| Healthcare Services Colombia | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;105 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;365 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1050 | 0% | -4% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Colombia* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;106 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;369 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1054 | 1% | -3% |
| &nbsp;&nbsp;&nbsp;*- Holding and eliminations* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) |  |  |
| Healthcare Services Peru & Oncosalud Peru | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;141 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;488 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1423 | 9% | 9% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;279 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;812 | 9% | 8% |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;85 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;294 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;861 | 8% | 8% |
| &nbsp;&nbsp;&nbsp;*- Holding and eliminations* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(24) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(84) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(249) | 6% | 5% |
| **Total Revenue** | **322** | **1117** | **3253** | **-1%** | **-2%** |
| Cost of sales and services | (201) | (698) | (2018) | 3% | -1% |
| **Gross profit** | **121** | **419** | **1235** | **-7%** | **-4%** |
| *Gross margin* |  | *37.5%* | *38.0%* | *-2.4 p.p.* | *-0.9 p.p.* |
| Selling expenses | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(59) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(167) | 8% | 7% |
| Administrative expenses | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(58) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(200) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(590) | 2% | 0% |
| (Loss) reversal for impairment of trade receivables | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(29) | -78% | 3% |
| Other income and expenses, net | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32 | -80% | -56% |
| **Operating profit** | **48** | **166** | **481** | **-28%** | **-19%** |
| Finance income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15 | -27% | -16% |
| Finance income from exchange difference | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;145 | 39% | 3.6x |
| Finance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(33) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(116) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(359) | -16% | -21% |
| Finance costs from exchange difference | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |  |  |
| **Net finance cost** | **(21)** | **(72)** | **(199)** | **-31%** | **-56%** |
| Share of profit of equity accounted investees | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | 3 | 8 | 45% | 24% |
| **Profit (loss) before tax** | **28** | **97** | **291** | **-24%** | **1.0x** |
| Income tax expense (benefit) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(44) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(116) | 63% | 1.5x |
| **Net Income (Loss)** | **15** | **53** | **175** | **-47%** | **0.7x** |
| **EBITDA** |  |  |  |  |  |
| Healthcare Services Mexico | 22 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;212 | -52% | -40% |
| Healthcare Services Colombia | 14 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;148 | 12% | -2% |
| Healthcare Services Peru & Oncosalud Peru | 31 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;107 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;309 | 13% | 13% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* | *12* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;42 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;117 | *13%* | *4%* |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* | *19* | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;65 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;192 | *13%* | *20%* |
| Holding and eliminations | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15) |  |  |
| **Total EBITDA** | **65** | **226** | **655** | **-21%** | **-15%** |
| **Adjusted EBITDA** |  |  |  |  |  |
| Healthcare Services Mexico | 22 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;77 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;245 | -32% | -23% |
| Healthcare Services Colombia | 15 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;51 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;150 | 14% | -1% |
| Healthcare Services Peru & Oncosalud Peru | 32 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;111 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;314 | 15% | 14% |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* | *13* | *44* | *119* | *14%* | *3%* |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* | *19* | *67* | *194* | *16%* | *22%* |
| Holding and eliminations | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) | 17% | 96% |
| **Total Adjusted EBITDA** | **67** | **232** | **696** | **-7%** | **-6%** |
| **Adjusted EBITDA Margin** |  |  |  |  |  |
| Healthcare Services Mexico |  | 29.0% | 31.4% | -6.9 p.p. | -2.9 p.p. |
| Healthcare Services Colombia |  | 13.9% | 14.3% | 1.5 p.p. | 0.3 p.p. |
| Healthcare Services Peru & Oncosalud Peru |  | 22.7% | 22.0% | 1.2 p.p. | 1.0 p.p. |
| &nbsp;&nbsp;&nbsp;*- Healthcare Services Peru* |  | *15.7%* | *14.7%* | 0.6 p.p. | -0.7 p.p. |
| &nbsp;&nbsp;&nbsp;*- Oncosalud Peru* |  | *22.9%* | *22.6%* | 1.6 p.p. | 2.5 p.p. |
| ***Adjusted EBITDA Margin*** |  | ***20.8%*** | ***21.4%*** | **-1.3 p.p.** | **-0.8 p.p.** |

---

**Statement of Cash Flows (1/2)**

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **YTD 25 (USD)** | **YTD 25** | **YTD 24** | **Δ YTD 25 vs YTD 24** |
| **Cash flows from operating activities** |  |  |  |  |
| (Loss) profit for the period | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;50 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;175 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;75 |
| **Adjustments for:** |  |  |  |  |
| Depreciation | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;89 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) |
| Depreciation of right-of-use assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Amortization | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;59 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Other income for reversal of others accounts payable to former shareholders | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(47) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47 |
| (Reversal) Impairment of inventories | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 |
| Equity-settled share-based payment transactions | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 |
| Gain (loss) on disposal of property furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) |
| Loss on disposal of right-of-use assets net of leases | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| Loss on disposal of intangibles | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| (Reversal) loss for impairment of trade receivables | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;28 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Share of profit of equity-accounted investees | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(7) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| Technical provisions and other provisions | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) |
| Finance income | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(46) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(161) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(50) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(111) |
| Finance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;104 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;359 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;503 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(144) |
| Tax expense | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;33 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;116 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69 |
| **Net changes in assets and liabilities** |  |  |  |  |
| Trade accounts receivable and other assets | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(38) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(132) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(285) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;153 |
| Inventories | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7 |
| Trade accounts payable and other accounts payable | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;164 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(129) |
| Provisions and employee benefits | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) |
| Insurance contract liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8 |
| **Cash generated from operating activities** | **168** | **582** | **612** | **(30)** |
| Income tax paid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(45) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(155) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(154) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| Interest received | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) |
| **Net cash from operating activities** | **127** | **440** | **475** | **(35)** |

---

**Statement of Cash Flows (2/2)**

(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **YTD 25 (USD)** | **YTD 25** | **YTD 24** | **Δ YTD 25 vs YTD 24** |
| **Cash flows from investing activities** |  |  |  |  |
| Payment for accounts payables to former shareholder | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(21) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(18) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) |
| Purchase of properties furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(19) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(66) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(58) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(8) |
| Purchase of intangibles | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(13) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(47) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(35) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(12) |
| Dividends from equity-accounted investees | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Purchase of other investments net of sales | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(16) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22 |
| Proceeds from sale of property furniture and equipment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6 |
| Payment for contingent consideration | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(47) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;47 |
| **Net cash used in investing activities** | **(34)** | **(119)** | **(173)** | **54** |
| **Cash flows from financing activities** |  |  |  |  |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1268 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1268) |
| Proceeds from settlement of derivatives - interest rate swaps | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(9) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10) |
| Payments of initial public offering costs | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(16) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16 |
| Proceeds from loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;311 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1079 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;745 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;334 |
| Payment for loans and borrowings | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(312) | &nbsp;&nbsp;&nbsp;&nbsp;(1084) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(702) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(382) |
| Payment for lease liabilities | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(10) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(34) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(34) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Penalty paid for debt prepayment | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(0) |
| Payment for costs of Extinguishment of debt | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17 |
| Payment for derivatives premiums | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(17) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(36) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 |
| Payment for settlement of derivatives - interest rate forward | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- |
| Interest paid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(78) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(271) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(317) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46 |
| Dividends paid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1 |
| Acquisition of non-controlling interest | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;- | &nbsp;&nbsp;&nbsp;&nbsp;(1218) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1218 |
| **Net cash used in financing activities** | **(97)** | **(336)** | **(328)** | **(8)** |
| Net (decrease) increase in cash and cash equivalents | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(26) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10 |
| Cash and cash equivalents at January 1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;68 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;236 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;241 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) |
| Effect of movements in exchange rates on cash held | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(15) | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 |
| **Cash and cash equivalents at the end of the period** | **65** | **226** | **200** | **25** |

---

**Historical Financial Metrics** 

*(Figures in millions of Soles and millions of US Dollars, unless expressed otherwise)*

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **3Q'23** | **4Q'23** | **1Q'24** | **2Q'24** | **3Q'24** | **4Q'24** | **1Q'25** | **2Q'25** | **3Q'25** |
| **Revenue** |  |  |  |  |  |  |  |  |  |
| Oncosalud Peru | 237 | 244 | 253 | 269 | 273 | 276 | 281 | 286 | 294 |
| Healthcare Services Peru | 230 | 225 | 241 | 255 | 255 | 245 | 263 | 269 | 279 |
| Healthcare Services Colombia | 324 | 335 | 349 | 378 | 363 | 353 | 339 | 346 | 369 |
| Healthcare Services Mexico | 294 | 284 | 308 | 302 | 316 | 268 | 243 | 274 | 264 |
| Holding and eliminations | (69) | (67) | (76) | (83) | (80) | (79) | (84) | (81) | (88) |
| **Total revenue from contracts with customers** | **1015** | **1021** | **1076** | **1120** | **1127** | **1063** | **1042** | **1094** | **1117** |
| Cost of sales and services | (643) | (645) | (662) | (693) | (677) | (629) | (660) | (660) | (698) |
| **Gross profit** | **372** | **376** | **414** | **427** | **449** | **434** | **382** | **434** | **419** |
| Selling expenses | (55) | (42) | (53) | (48) | (55) | (42) | (54) | (54) | (59) |
| Administrative expenses | (177) | (193) | (191) | (202) | (195) | (201) | (182) | (208) | (200) |
| Impairment losses on trade receivables | (1) | (2) | 0 | (3) | (25) | (13) | (16) | (8) | (5) |
| Other expenses | 0 | (21) | 0 | 0 | 0 | (2) | 0 | 0 | 0 |
| Other income | 10 | 13 | 11 | 8 | 54 | 14 | 9 | 12 | 11 |
| **Operating profit** | **149** | **130** | **182** | **183** | **229** | **190** | **139** | **176** | **166** |
| Finance income | 3 | 6 | 6 | 7 | 6 | 7 | 6 | 5 | 4 |
| Finance income from exchange difference | 0 | 33 | 3 | 0 | 28 | (31) | 37 | 68 | 40 |
| Finance costs | (158) | (357) | (177) | (139) | (138) | (138) | (123) | (120) | (116) |
| Finance costs from exchange difference | (17) | 17 | 0 | (49) | 0 | 8 | 0 | 0 | 0 |
| **Net finance cost** | **(172)** | **(302)** | **(168)** | **(182)** | **(103)** | **(155)** | **(80)** | **(46)** | **(72)** |
| Share of profit of equity-accounted investees | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 2 | 3 |
| **Profit (loss) before tax** | **(20)** | **(170)** | **16** | **3** | **127** | **37** | **62** | **132** | **97** |
| Income tax (expense) benefit | 3 | (50) | (25) | 5 | (27) | (13) | (24) | (48) | (44) |
| **Net Income** | **(18)** | **(219)** | **(8)** | **8** | **101** | **24** | **38** | **84** | **53** |
| **EBITDA** | **210** | **188** | **241** | **241** | **286** | **244** | **195** | **234** | **226** |
| **EBITDA Adjustments** |  |  |  |  |  |  |  |  |  |
| Net Income | (18) | (219) | (8) | 8 | 101 | 24 | 38 | 84 | 53 |
| Income tax expense | (3) | 50 | 25 | (5) | 27 | 13 | 24 | 48 | 44 |
| Net finance cost | 172 | 302 | 168 | 182 | 103 | 155 | 80 | 46 | 72 |
| Depreciation and amortization | 59 | 56 | 56 | 56 | 55 | 52 | 53 | 55 | 57 |
| *(a) Pre-operating expenses* | *1* | *0* | *0* | *2* | *0* | *0* | *0* | *0* | *(0)* |
| *(b) Business development expenses* | *0* | *0* | *0* | *1* | *(44)* | *3* | *24* | *4* | *4* |
| *(c) Change in fair value of earn-out liabilities* | *0* | *21* | *0* | *0* | *0* | *0* | *0* | *0* | *0* |
| *(d) Stock-based consideration* | *0* | *4* | *0* | *0* | *6* | *3* | *3* | *3* | *3* |
| *(e) Personnel non-recurring compensation* | *0* | *0* | *0* | *4* | *2* | *5* | *0* | *0* | *0* |
| **Adjusted EBITDA** | **211** | **213** | **241** | **248** | **250** | **254** | **222** | **241** | **232** |

---

**Key Operating Metrics**

---

| | | | |
|:---|:---|:---|:---|
| | **YTD 25** | **YTD 24** | **Δ YTD 25 vs YTD 24** |
| <br>**Oncosalud Peru** |  |  |  |
| **Plan memberships <sup>(1) (2)</sup>** | **1395509** | **1296049** | **8%** |
| **Average monthly revenue per plan member <sup>(3)</sup>** | **S/ 60.99** | **S/ 59.72** | **2.1%** |
| **Preventive check-ups <sup>(4)</sup>** | **93650** | **78315** | **19.6%** |
| **Patients treated <sup>(5)</sup>** | **65440** | **52907** | **23.7%** |
| **Medical loss ratio <sup>(6)</sup>** | **54.5%** | **57.6%** | **-3.1 p.p** |
| **Healthcare Services** |  |  |  |
| **Total bed capacity <sup>(1)(7)</sup>** | **2224** | **2199** | **1.1%** |
| **Surgeries <sup>(8)</sup>** | **62946** | **67253** | **-6.4%** |
| **Emergency treatments <sup>(9)</sup>** | **267775** | **274982** | **-2.6%** |
| **Operating capacity utilization <sup>(10)</sup>** | **77.1%** | **81.3%** | **-4.2 p.p** |
| **Total capacity utilization <sup>(11)</sup>** | **64.3%** | **67.3%** | **-3.0 p.p** |

---

1) As of period end and as reported to the National Superintendence of Health Susalud. Includes Oncology plans and Health plans.

2) Includes active plan members and inactive members. Inactive members are defined as those plan members that have not paid monthly fees due for up to three months. As of September 30, 2025, we had 1,290,056 active members and 105,453 inactive members.

3) Total revenue for the period corresponding to insurance revenue in the Oncosalud Peru segment divided by the average number of plan members during the period, divided by the number of months in the period.

4) Preventive check-ups consider Oncology check-ups at the Centro de Bienestar Ambulatorio – CBA (wellness center) in Lima, Peru. The number of Healthcare checkups is negligible.

5) Number of individual plan members receiving treatment for cancer during the period, which may include multiple instances of treatment per plan member.

6) MLR is calculated as (i) claims for medical treatment generated by our prepaid oncology and general healthcare plans plus (ii) technical reserves relating to plan members treated pursuant to such plans, whether at our facilities or third-party facilities, divided by revenue generated by our prepaid oncology and general healthcare plans.

7) Includes all beds within the Healthcare Network and excludes 109 Oncology beds.

8) Number of surgeries includes surgeries outpatient surgeries and cesarean sections

9) Emergency care includes the number of visits in the emergency room and may include several visits per patient.

10) Operating capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of operating beds, times (ii) total number of days during the period.

11) Total capacity utilization (Occupancy) is calculated as (i) (x) total number of days in which any of our beds had a hospitalized patient during the period divided by (y) total number of beds, times (ii) total number of days during the period.

## Exhibit 99.2

**Exhibit 99.2**

Auna S.A. and <br> Subsidiaries<br> Condensed Consolidated Interim <br> Financial Statements<br>**September 30, 2025**<br>

**Auna S.A. and Subsidiaries** 

Condensed Consolidated Interim <br> Financial Statements

**September 30, 2025**

---

| | |
|:---|:---|
| **Contents** | **Page** |
| Condensed Consolidated Interim Statement of Financial Position | 1 |
| Condensed Consolidated Interim Statement of Profit or Loss and Other |  |
| Comprehensive Income | 2 |
| Condensed Consolidated Interim Statement of Changes in Equity | 3 |
| Condensed Consolidated Interim Statement of Cash Flows | 4 |
| Operating Segments | 5 - 10 |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Condensed Consolidated Interim Statement of Financial Position |
| As of September 30, 2025 and December 31, 2024 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| *In thousands of soles* | **September 30, <br> 2025** | **December 31, <br> 2024** | *In thousands of soles* | **September 30,** <br> **2025**  | **December 31, <br> 2024** |
| **Assets** |  |  | **Liabilities** |  |  |
| **Current assets** |  |  | **Current liabilities** |  |  |
| Cash and cash equivalents | 225710 | 235745 | Loans and borrowings | 658045 | 654233 |
| Trade accounts receivable | 1075980 | 961886 | Lease liabilities | 31213 | 32459 |
| Other assets | 255687 | 253283 | Trade accounts payable | 945820 | 931265 |
| Inventories | 148637 | 143764 | Other accounts payable | 320967 | 289563 |
| Derivative financial instruments | 185 | 8962 | Provisions | 10194 | 12246 |
| Other investments | 99688 | 100228 | Derivative financial instruments | 38242 | 15273 |
| **Total current assets** | **1805887** | **1703868** | Insurance contract liabilities | 9384 | 10098 |
|  |  |  | Deferred income | 104 | 138 |
| **Non-current assets** |  |  | **Total current liabilities** | **2013969** | **1945275** |
| Trade accounts receivable | 509 | 571 |  |  |  |
| Other assets | 26683 | 24433 | **Non-current liabilities** |  |  |
| Investments in associates and joint venture | 29451 | 25405 | Loans and borrowings | 2867818 | 2965541 |
| Other investments | 395 | 282 | Lease liabilities | 97695 | 115429 |
| Property, furniture, and equipment | 2304282 | 2280123 | Trade accounts payable | 1777 | 2741 |
| Intangible assets | 2733792 | 2656888 | Other accounts payable | 134279 | 73150 |
| Right-of-use assets | 115723 | 131062 | Derivative financial instruments | 41076 | 27097 |
| Investment properties | 6287 | 6058 | Deferred tax liabilities | 310103 | 328370 |
| Derivative financial instruments | 37753 | 58510 | Deferred income | 108 | 177 |
| Deferred tax assets | 221260 | 193520 | **Total non-current liabilities** | **3452856** | **3512505** |
| **Total non-current assets** | **5476135** | **5376852** | **Total liabilities** | **5466825** | **5457780** |
|  |  |  | **Equity** |  |  |
|  |  |  | Share capital | 17389 | 17387 |
|  |  |  | Share premium | 1209715 | 1208586 |
|  |  |  | Reserves | 538678 | 524776 |
|  |  |  | Retained losses | (108032) | (273533) |
|  |  |  | **Equity attributable to the owner of the Company** | **1657750** | **1477216** |
|  |  |  | Non-controlling interest | 157447 | 145724 |
|  |  |  | **Total equity** | **1815197** | **1622940** |
| **Total assets** | **7282022** | **7080720** | **Total liabilities and equity** | **7282022** | **7080720** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Condensed Consolidated Interim Statement of Profit or Loss and Other Comprehensive Income |
| For the three and nine months ended September 30, 2025 and 2024 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| *In thousands of soles* | **Three-month period ended <br> September 30** | **Three-month period ended <br> September 30** | **Nine-month period ended <br> September 30** | **Nine-month period ended <br> September 30** |
| *In thousands of soles* | **2025** | **2024** | **2025** | **2024** |
| Revenue |  |  |  |  |
| Insurance revenue | 285596 | 275189 | 837798 | 783721 |
| Healthcare services revenue | 744365 | 765595 | 2163424 | 2300855 |
| Sale of medicines | 87011 | 85907 | 251557 | 238628 |
| **Total revenue from contracts with customers** | **1116972** | **1126691** | **3252779** | **3323204** |
| Cost of sales and services | (697849) | (677318) | (2017637) | (2032076) |
| **Gross profit** | **419123** | **449373** | **1235142** | **1291128** |
| Selling expenses | (59114) | (54534) | (166941) | (155437) |
| Administrative expenses | (199831) | (195185) | (590463) | (587671) |
| Loss for impairment of trade receivables | (5481) | (25155) | (28825) | (27990) |
| Other income | 10918 | 54400 | 32236 | 73464 |
| **Operating profit** | **165615** | **228899** | **481149** | **593494** |
| Finance income | 4269 | 5845 | 15356 | 18249 |
| Finance income from exchange difference | 39686 | 28459 | 145202 | 31374 |
| Finance costs | (115730) | (137789) | (359232) | (453669) |
| Finance costs from exchange difference | - | - | - | (49495) |
| **Net finance cost** | **(71775)** | **(103485)** | **(198674)** | **(453541)** |
| **Share of profit of equity-accounted investees** | **2899** | **1998** | **8073** | **6514** |
| **Profit before tax** | **96739** | **127412** | **290548** | **146467** |
| Income tax expense | (43798) | (26899) | (115622) | (46366) |
| **Profit for the period** | **52941** | **100513** | **174926** | **100101** |
| **Other comprehensive income (loss)** |  |  |  |  |
| **Items that are or may be reclassified subsequently to profit or loss** |  |  |  |  |
| Cash flow hedges | (4847) | (859) | (36341) | (16780) |
| Foreign operations – foreign currency translation differences | 34507 | (208764) | 101750 | (324938) |
| Other investments at FVOCI – net change in fair value | 410 | 927 | 1036 | 1486 |
| Income tax | 1405 | 1108 | 10667 | 4416 |
| **Other comprehensive income (loss) for the period, net of tax** | **31475** | **(207588)** | **77112** | **(335816)** |
| **Total comprehensive income (loss) for the period** | **84416** | **(107075)** | **252038** | **(235715)** |
| **Income attributable to:** |  |  |  |  |
| Owner of the Company | 48094 | 97894 | 165501 | 88312 |
| Non-controlling interest | 4847 | 2619 | 9425 | 11789 |
|  | **52941** | **100513** | **174926** | **100101** |
| **Total comprehensive income (loss) attributable to:** |  |  |  |  |
| Owner of the Company | 79791 | (102534) | 240315 | (234415) |
| Non-controlling interest | 4625 | (4541) | 11723 | (1300) |
|  | **84416** | **(107075)** | **252038** | **(235715)** |
| **Earnings per share** |  |  |  |  |
| Basic earnings per share | 0.65 | 1.32 | 2.24 | 1.36 |
| Diluted earnings per share | 0.65 | 1.32 | 2.23 | 1.35 |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Condensed Consolidated Interim Statement of Changes in Equity |
| For the nine months ended September 30, 2025 and 2024 |

---

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | **Equity attributable to the owner of the Company** | **Equity attributable to the owner of the Company** | **Equity attributable to the owner of the Company** | **Equity attributable to the owner of the Company** | **Equity attributable to the owner of the Company** | **Equity attributable to the owner of the Company** | | | |
| <br>*In thousands of soles* | <br>**Share** <br> **capital**  | **Share** <br> **Premium** | **Other** <br> **capital** <br> **reserve** | **Translation reserve** | **Cost of<br> hedging** <br> **reserve**  | **Hedging** <br> **reserve**  | **Merger** <br> **and other reserves**  | **Shared-based payment reserve** | **Retained (losses) earnings** | <br>**Total** | <br>**Non-<br> controlling <br> interest** | <br>**Total** <br> **equity**  |
| **Balances as of December 31, 2023** | **8820** | **-** | **79782** | **140066** | **6422** | **(29548)** | **1626642** | **-** | **(366899)** | **1465285** | **311281** | **1776566** |
| **Balances as of January 1, 2024** | **8820** | **-** | **79782** | **140066** | **6422** | **(29548)** | **1626642** | **-** | **(366899)** | **1465285** | **311281** | **1776566** |
| Profit for the period |  |  |  |  |  |  |  |  | 88312 | 88312 | 11789 | 100101 |
| Other comprehensive loss for the period | - | - | - | (311849) | (11789) | (575) | 1486 | - | - | (322727) | (13089) | (335816) |
| **Total comprehensive loss for the period** | **-** | **-** | **-** | **(311849)** | **(11789)** | **(575)** | **1486** | **-** | **88312** | **(234415)** | **(1300)** | **(235715)** |
| Issuance of common stock, net of issuance costs | 1112 | 1207474 |  |  |  |  |  |  |  | 1208586 |  | 1208586 |
| Capitalization of merger reserve | 7453 |  |  |  |  |  | (7453) |  |  |  |  |  |
| Reclassification of shared-based payment reserve |  |  |  |  |  |  |  | 3675 | (3675) |  |  |  |
| Issuance of shares | 2 | 3673 |  |  |  |  |  | (3675) |  |  |  |  |
| Acquisition of non-controlling interest |  |  |  | 18909 |  |  | (1076628) |  |  | (1057719) | (159910) | (1217629) |
| Derecognition of put and call liability |  |  |  |  |  |  | 131152 |  |  | 131152 |  | 131152 |
| Equity-settled share-based payment | - | - | - | - | - | - | - | 6269 | - | 6269 | - | 6269 |
| **Total transactions with the owner of the Company** | **8567** | **1211147** | **-** | **18909** | **-** | **-** | **(952929)** | **6269** | **(3675)** | **288288** | **(159910)** | **128378** |
| **Balances as of September 30, 2024** | **17387** | **1211147** | **79782** | **(152874)** | **(5367)** | **(30123)** | **675199** | **6269** | **(282262)** | **1519158** | **150071** | **1669229** |
| **Balances as of December 31, 2024** | **17387** | **1208586** | **93012** | **(232770)** | **15392** | **(36494)** | **676491** | **9145** | **(273533)** | **1477216** | **145724** | **1622940** |
| Profit for the period |  |  |  |  |  |  |  |  | 165501 | 165501 | 9425 | 174926 |
| Other comprehensive income for the period | - | - | - | 99452 | (38709) | 13035 | 1036 | - | - | 74814 | 2298 | 77112 |
| **Total comprehensive income for the period** | **-** | **-** | **-** | **99452** | **(38709)** | **13035** | **1036** | **-** | **165501** | **240315** | **11723** | **252038** |
| Issuance of shares | 2 | 1129 |  |  |  |  |  | (1131) |  |  |  |  |
| Equity transaction for mandatory purchase of NCI |  |  |  |  |  |  | (68111) |  |  | (68111) |  | (68111) |
| Equity-settled share-based payment | - | - | - | - | - | - |  | 8330 | - | 8330 | - | 8330 |
| **Total transactions with the owner of the Company** | **2** | **1129** | **-** | **-** | **-** | **-** | **(68111)** | **7199** | **-** | **(59781)** | **-** | **(59781)** |
| **Balances as of September 30, 2025** | **17389** | **1209715** | **93012** | **(133318)** | **(23317)** | **(23459)** | **609416** | **16344** | **(108032)** | **1657750** | **157447** | **1815197** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Condensed Consolidated Interim Statement of Cash Flows |
| For the nine months ended September 30, 2025 and 2024 |

---

---

| | | |
|:---|:---|:---|
| | **Nine-month period ended September 30** | **Nine-month period ended September 30** |
| <br>*In thousands of soles* | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Profit for the period | 174926 | 100101 |
| **Adjustments for:** |  |  |
| Depreciation | 86118 | 89022 |
| Depreciation of right-of-use assets | 21321 | 20664 |
| Amortization | 58559 | 57567 |
| Impairment (reversal) of inventories | 120 | (3392) |
| Equity-settled share-based payment transactions | 8330 | 6269 |
| Gain (loss) on disposal of property, furniture, and equipment | (1275) | 1962 |
| Gain (loss) on disposal of right-of-use assets net of leases liabilities | (9) | 71 |
| Loss on disposal of intangibles |  | 1151 |
| Loss for Impairment of trade receivables | 28825 | 27990 |
| Share of profit of equity-accounted investees | (8073) | (6514) |
| Provisions | 1108 | 4053 |
| Other income for reversal of others accounts payable to former shareholders |  | (46613) |
| Finance income | (160558) | (49623) |
| Finance costs | 359232 | 503164 |
| Tax expense | 115622 | 46366 |
| **Net changes in assets and liabilities:** |  |  |
| Trade accounts receivable and other assets | (132035) | (285348) |
| Inventories | (1443) | (7946) |
| Trade accounts payable and other accounts payable | 35230 | 163828 |
| Provisions and employee benefits | (3514) | (2260) |
| Insurance contract liabilities | (753) | (8403) |
| **Cash generated from operating activities** | **581731** | **612109** |
| Income tax paid | (155234) | (153520) |
| Interest received | 13281 | 16363 |
| **Net cash from operating activities** | **439778** | **474952** |
| **Cash flows from investing activities** |  |  |
| Payment for accounts payables to former shareholder | (20855) | (18476) |
| Purchase of properties, furniture, and equipment | (66405) | (58013) |
| Proceeds from sale of property, furniture, and equipment | 6493 | 216 |
| Purchase of intangibles | (46556) | (34881) |
| Dividends from equity-accounted investees | 3169 | 1718 |
| Purchase of other investments, net of sales | 5249 | (16287) |
| Payment for contingent consideration | - | (46991) |
| **Net cash used in investing activities** | **(118905)** | **(172714)** |
| **Cash flows from financing activities** |  |  |
| Proceeds from issuance of common stock in initial public offering, net of issuance costs |  | 1267794 |
| Payments of initial public offering costs |  | (15908) |
| Proceeds from loans and borrowings | 1078860 | 744818 |
| Payment for loans and borrowings | (1084162) | (701878) |
| Payment for lease liabilities | (33516) | (34028) |
| Penalty paid for debt prepayment | (81) |  |
| Payment for derivatives premiums | (16863) | (36458) |
| Payment for costs of Extinguishment of debt |  | (16607) |
| Interest paid | (271105) | (317243) |
| (Payment for) proceeds from settlement of derivatives - interest rate swaps | (9336) | 343 |
| Dividend paid |  | (1174) |
| Acquisition of non-controlling interest | - | (1217629) |
| **Net cash used in financing activities** | **(336203)** | **(327970)** |
| Net decrease in cash and cash equivalents | (15330) | (25732) |
| Cash and cash equivalents at January 1 | 235745 | 241133 |
| Effect of movements in exchange rates on cash held | 5295 | (14908) |
| **Cash and cash equivalents at September 30** | **225710** | **200493** |
| **Transactions not representing cash flows** |  |  |
| Assets acquired through finance lease and other financing | 10493 | 9119 |
| Assets acquired from suppliers in installments | 22163 | 6455 |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2025 |

---

**Operating Segments**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** **Basis for segmentation** 

The Group has determined four reportable segments. These operating segments are components of a company about which separate financial information is available that is regularly evaluated by the Board of Directors (Chief operating decision maker) in deciding how to allocate resources and assess performance.

The following summary describes the operations of each reportable segment.

---

| | |
|:---|:---|
| **Reportable segments** | **Operations** |
| Oncosalud Peru | &nbsp;&nbsp;Including our prepaid oncologic healthcare plans and healthcare services related to the treatment of cancer. |
| Healthcare services in Peru | &nbsp;&nbsp;Corresponds to medical services within the network of clinics and health centers in Peru. |
| Healthcare services in Colombia | &nbsp;&nbsp;Corresponds to medical services within the network of clinics and health centers in Colombia. |
| Healthcare services in Mexico | &nbsp;&nbsp;Corresponds to medical services within the network of clinics and health centers, and the insurance business in Mexico. |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** **Information about reportable segments** 

Information related to each reportable segment is set out below. Segment profit (loss) before tax is used to measure performance because the chief operating decision maker believes that this information is the most relevant for the Group.

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2025 |

---

For the three months period ended September 30, 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *In thousands of soles* | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** |  |  |
| *In thousands of soles* | **Oncosalud** <br> **Peru**  | **Healthcare services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable segments** | **Holding and eliminations** | **Total** |
| **2025** |  |  |  |  |  |  |  |
| External revenues | 286410 | 201887 | 364566 | 264109 | 1116972 |  | 1116972 |
| Inter-segment revenue (i) | 7287 | 77203 | 3957 | - | 88447 | (88447) | - |
| **Segment revenue** | **293697** | **279090** | **368523** | **264109** | **1205419** | **(88447)** | **1116972** |
| External cost of service | (83944) | (185953) | (275633) | (152319) | (697849) |  | (697849) |
| Inter-segment cost of service (i) | (73209) | (9290) | - | - | (82499) | 82499 | - |
| **Segment cost of service** | **(157153)** | **(195243)** | **(275633)** | **(152319)** | **(780348)** | **82499** | **(697849)** |
| **Gross profit** | **136544** | **83847** | **92890** | **111790** | **425071** | **(5948)** | **419123** |
| External selling expenses | (47813) | (6140) | (1245) | (3892) | (59090) | (24) | (59114) |
| **Segment selling expenses** | **(47813)** | **(6140)** | **(1245)** | **(3892)** | **(59090)** | **(24)** | **(59114)** |
| External administrative expenses | (18545) | (29996) | (51212) | (58424) | (158177) |  | (158177) |
| Inter-segment administrative expenses | (757) | (2037) |  |  | (2794) | 2794 |  |
| Corporate expenses | (17266) | (17096) | (2462) | (1735) | (38559) | (3095) | (41654) |
| **Segment administrative expenses** | **(36568)** | **(49129)** | **(53674)** | **(60159)** | **(199530)** | **(301)** | **(199831)** |
| **Impairment losses on trade receivables** | **(573)** | **(1138)** | **(2405)** | **(1379)** | **(5495)** | **14** | **(5481)** |
| Other income | 960 | 1889 | 1029 | 7146 | 11024 | (106) | 10918 |
| Inter-segment other income | 3002 | 238 | - | - | 3240 | (3240) | - |
| **Other income** | **3962** | **2127** | **1029** | **7146** | **14264** | **(3346)** | **10918** |
| **Segment operating profit (loss)** | **55552** | **29567** | **36595** | **53506** | **175220** | **(9605)** | **165615** |
| Share of profit of equity accounted investees, net of taxes | 782 |  | 2117 |  | 2899 |  | 2899 |
| Exchange difference, net | 756 | 483 | 17255 | 8471 | 26965 | 12721 | 39686 |
| Interest expense, net | (3397) | (9838) | (23032) | (41453) | (77720) | (33741) | (111461) |
| **Segment profit (loss) before tax** | **53693** | **20212** | **32935** | **20524** | **127364** | **(30625)** | **96739** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (9164) | (12397) | (10749) | (22205) | (54515) | (2796) | (57311) |
| Capital expenditure | (7351) | (4297) | (5104) | (9583) | (26335) | (3118) | (29453) |
| **Segment assets** | **95919** | **41289** | **80639** | **46250** | **264097** | **(149202)** | **114895** |
| **Segment liabilities** | **64688** | **30808** | **103753** | **34908** | **234157** | **(138445)** | **95712** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2025 |

---

For the three months period ended September 30, 2024:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *In thousands of soles* | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** |  |  |
| *In thousands of soles* | **Oncosalud** <br> **Peru**  | **Healthcare services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable segments** | **Holding and eliminations** | **Total** |
| **2024** |  |  |  |  |  |  |  |
| External revenues | 262513 | 185194 | 363231 | 315753 | 1126691 |  | 1126691 |
| Inter-segment revenue (i) | 10230 | 69800 | - | - | 80030 | (80030) | - |
| **Segment revenue** | **272743** | **254994** | **363231** | **315753** | **1206721** | **(80030)** | **1126691** |
| External cost of service | (76691) | (169954) | (263471) | (167202) | (677318) |  | (677318) |
| Inter-segment cost of service (i) | (69847) | (9227) | - | - | (79074) | 79074 | - |
| **Segment cost of service** | **(146538)** | **(179181)** | **(263471)** | **(167202)** | **(756392)** | **79074** | **(677318)** |
| **Gross profit** | **126205** | **75813** | **99760** | **148551** | **450329** | **(956)** | **449373** |
| External selling expenses | (44449) | (4995) | (1083) | (3861) | (54388) | (146) | (54534) |
| **Segment selling expenses** | **(44449)** | **(4995)** | **(1083)** | **(3861)** | **(54388)** | **(146)** | **(54534)** |
| External administrative expenses | (19932) | (26586) | (48237) | (56530) | (151285) |  | (151285) |
| Inter-segment administrative expenses | (94) | (1176) |  |  | (1270) | 1270 |  |
| Corporate expenses | (15355) | (12658) | (2952) | (2233) | (33198) | (10702) | (43900) |
| **Segment administrative expenses** | **(35381)** | **(40420)** | **(51189)** | **(58763)** | **(185753)** | **(9432)** | **(195185)** |
| **Impairment losses on trade receivables** | **(246)** | **(5898)** | **(16258)** | **(2715)** | **(25117)** | **(38)** | **(25155)** |
| Other income | 753 | 1796 | 884 | 51355 | 54788 | (388) | 54400 |
| Inter-segment other income | 2464 | 195 | - | - | 2659 | (2659) | - |
| **Other income** | **3217** | **1991** | **884** | **51355** | **57447** | **(3047)** | **54400** |
| **Segment operating profit (loss)** | **49346** | **26491** | **32114** | **134567** | **242518** | **(13619)** | **228899** |
| Share of profit of equity accounted investees, net of taxes | 646 |  | 1352 |  | 1998 |  | 1998 |
| Exchange difference, net | (740) | 4696 | (1952) | (6013) | (4009) | 32468 | 28460 |
| Interest expense, net | (4548) | (11361) | (26836) | (59654) | (102399) | (29545) | (131945) |
| **Segment profit (loss) before tax** | **44704** | **19826** | **4678** | **68900** | **138108** | **(10696)** | **127412** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (8088) | (10757) | (10868) | (22834) | (52547) | (2311) | (54858) |
| Capital expenditure | (6210) | (10070) | (15132) | (11466) | (42878) | (3910) | (46788) |
| **Segment assets** | **36025** | **29546** | **(42947)** | **(327618)** | **(304994)** | **(37756)** | **(342750)** |
| **Segment liabilities** | **7997** | **17948** | **(127373)** | **(246771)** | **(348199)** | **(29054)** | **(377253)** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2025 |

---

For the nine months period ended September 30, 2025:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *In thousands of soles* | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** |  |  |
| *In thousands of soles* | **Oncosalud** <br> **Peru**  | **Healthcare services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable segments** | **Holding and eliminations** | **Total** |
| **2025** |  |  |  |  |  |  |  |
| External revenues | 833399 | 589160 | 1049582 | 780638 | 3252779 |  | 3252779 |
| Inter-segment revenue (i) | 27124 | 222345 | 3957 | - | 253426 | (253426) | - |
| **Segment revenue** | **860523** | **811505** | **1053539** | **780638** | **3506205** | **(253426)** | **3252779** |
| External cost of service | (236766) | (541383) | (774499) | (464989) | (2017637) |  | (2017637) |
| Inter-segment cost of service (i) | (220437) | (24475) | - | - | (244912) | 244912 | - |
| **Segment cost of service** | **(457203)** | **(565858)** | **(774499)** | **(464989)** | **(2262549)** | **244912** | **(2017637)** |
| **Gross profit** | **403320** | **245647** | **279040** | **315649** | **1243656** | **(8514)** | **1235142** |
| External selling expenses | (139235) | (16127) | (3912) | (8625) | (167899) | 958 | (166941) |
| **Segment selling expenses** | **(139235)** | **(16127)** | **(3912)** | **(8625)** | **(167899)** | **958** | **(166941)** |
| External administrative expenses | (56792) | (87774) | (146958) | (170501) | (462025) |  | (462025) |
| Inter-segment administrative expenses | (3190) | (5535) |  |  | (8725) | 8725 |  |
| Corporate expenses | (50765) | (49907) | (8216) | (5185) | (114073) | (14365) | (128438) |
| **Segment administrative expenses** | **(110747)** | **(143216)** | **(155174)** | **(175686)** | **(584823)** | **(5640)** | **(590463)** |
| **Impairment losses on trade receivables** | **(1681)** | **(10787)** | **(14058)** | **(2298)** | **(28824)** | **(1)** | **(28825)** |
| Other income | 2051 | 4990 | 6665 | 18526 | 32232 | 4 | 32236 |
| Inter-segment other income | 9264 | 708 | - | - | 9972 | (9972) | - |
| **Other income** | **11315** | **5698** | **6665** | **18526** | **42204** | **(9968)** | **32236** |
| **Segment operating profit (loss)** | **162972** | **81215** | **112561** | **147566** | **504314** | **(23165)** | **481149** |
| Share of profit of equity accounted investees, net of taxes | 2710 |  | 5363 |  | 8073 |  | 8073 |
| Exchange difference, net | 445 | 3549 | 58172 | 21756 | 83922 | 61280 | 145202 |
| Interest expense, net | (13865) | (30833) | (70923) | (127920) | (243541) | (100335) | (343876) |
| **Segment profit (loss) before tax** | **152262** | **53931** | **105173** | **41402** | **352768** | **(62220)** | **290548** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (26512) | (35969) | (30571) | (64831) | (157883) | (8115) | (165998) |
| Capital expenditure | (16236) | (28382) | (12934) | (36357) | (93909) | (7382) | (101291) |
| **Segment assets** | **2400793** | **1089598** | **2415418** | **3168617** | **9074426** | **(1792404)** | **7282022** |
| **Segment liabilities** | **1151687** | **687104** | **1335685** | **1925403** | **5099879** | **366946** | **5466825** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2025 |

---

For the three months period ended September 30, 2024:

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| *In thousands of soles* | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** | **Reportable segments** |  |  |
| *In thousands of soles* | **Oncosalud** <br> **Peru**  | **Healthcare services in Peru** | **Healthcare services in Colombia** | **Healthcare services in Mexico** | **Total reportable segments** | **Holding and eliminations** | **Total** |
| **2024** |  |  |  |  |  |  |  |
| External revenues | 764943 | 541969 | 1089741 | 926551 | 3323204 |  | 3323204 |
| Inter-segment revenue (i) | 29777 | 208944 | - | - | 238721 | (238721) | - |
| **Segment revenue** | **794720** | **750913** | **1089741** | **926551** | **3561925** | **(238721)** | **3323204** |
| External cost of service | (231214) | (502367) | (796509) | (501986) | (2032076) |  | (2032076) |
| Inter-segment cost of service (i) | (209253) | (27510) | - | - | (236763) | 236763 | - |
| **Segment cost of service** | **(440467)** | **(529877)** | **(796509)** | **(501986)** | **(2268839)** | **236763** | **(2032076)** |
| **Gross profit** | **354253** | **221036** | **293232** | **424565** | **1293086** | **(1958)** | **1291128** |
| External selling expenses | (125696) | (15195) | (4397) | (9543) | (154831) | (606) | (155437) |
| **Segment selling expenses** | **(125696)** | **(15195)** | **(4397)** | **(9543)** | **(154831)** | **(606)** | **(155437)** |
| External administrative expenses | (56903) | (77819) | (148839) | (185980) | (469541) |  | (469541) |
| Inter-segment administrative expenses | (265) | (3913) |  |  | (4178) | 4178 |  |
| Corporate expenses | (47688) | (42642) | (8857) | (6695) | (105882) | (12248) | (118130) |
| **Segment administrative expenses** | **(104856)** | **(124374)** | **(157696)** | **(192675)** | **(579601)** | **(8070)** | **(587671)** |
| **Impairment losses on trade receivables** | **(144)** | **(5494)** | **(19256)** | **(3130)** | **(28024)** | **34** | **(27990)** |
| Other income | 1944 | 4603 | 3662 | 63794 | 74003 | (539) | 73464 |
| Inter-segment other income | 7969 | 696 | - | - | 8665 | (8665) | - |
| **Other income** | **9913** | **5299** | **3662** | **63794** | **82668** | **(9204)** | **73464** |
| **Segment operating profit (loss)** | **133470** | **81272** | **115545** | **283011** | **613298** | **(19804)** | **593494** |
| Share of profit of equity accounted investees, net of taxes | 2589 |  | 3925 |  | 6514 |  | 6514 |
| Exchange difference, net | (2172) | (459) | (39659) | (18219) | (60509) | 42389 | (18120) |
| Interest expense, net | (14996) | (34532) | (84622) | (217964) | (352114) | (83307) | (435421) |
| **Segment profit (loss) before tax** | **118891** | **46281** | **(4811)** | **46828** | **207189** | **(60722)** | **146467** |
| **Other disclosures** |  |  |  |  |  |  |  |
| Depreciation and amortization | (23852) | (31470) | (32367) | (72901) | (160590) | (6663) | (167253) |
| Capital expenditure | (14156) | (25914) | (36994) | (21874) | (98938) | (9530) | (108468) |
| **Segment assets** | **2236871** | **1000236** | **2329354** | **3180661** | **8747122** | **(1597382)** | **7149740** |
| **Segment liabilities** | **1115412** | **647054** | **1360651** | **1992350** | **5115467** | **365044** | **5480511** |

---

---

| |
|:---|
| **Auna S.A. and Subsidiaries** |
| Notes to the Condensed Consolidated Interim Financial Statements |
| September 30, 2025 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Inter-segment cost of service (claims expense) from the Oncosalud Peru segment and intersegment revenue from our Healthcare Services
in Peru segment are presented on a gross basis by adding the corresponding profit margin markup by our Healthcare Services in Peru segment
and vice versa. Likewise, our Oncosalud Peru segment consolidates Oncocenter Peru S.A.C., a subsidiary providing healthcare services related
to the exclusive treatment of cancer. In the separate financial statements of Oncocenter Peru S.A.C., the revenue mainly consists of the
insurance claims expense recorded as cost of sales in the separate financial statements of Oncosalud S.A.C., our insurance subsidiary
that is also consolidated in Oncosalud Peru segment. In the segment consolidation process the related revenues from such healthcare services
are eliminated with the corresponding claims expense of our insurance subsidiary Oncosalud S.A.C., while the external cost (third parties)
of services incurred by Oncocenter Peru S.A.C. remains.